Retatrutide Shows Promise as Triple Hormone Agonist for Obesity | Retatrutide News

Retatrutide, a triple hormone receptor agonist, is being studied for obesity treatment. Eli Lilly's development could impact future obesity therapies.
Clinical Trials · November 4, 2026